In the spotlight

Small Caps reports on EVE Health Group (ASX: EVE)'s first commercial purchase order for its proprietary gummy-format pharmaceutical product Dyspro. Dyspro is a pharmaceutical-grade formulation containing a validated blend of cannabinoid-derived active ingredients to support women experiencing dysmenorrhoea (painful menstruation) and related health concerns.

Small Caps reports on EVE Health Group (ASX: EVE)'s completion of its strategic acquisition of biotech company Nextract and key appointments. The successful purchase adds significant development upside in the $8.1 billion erectile dysfunction (ED) market, with Nextract’s lead product targeting therapeutic onset within 15 minutes of dosage.

EVE Health (ASX: EVE) incoming Chief Executive Officer, Damian Wood joins Jess Fertig on Small Caps to discuss EVE's strategic clinic partnership with TeleDocs Clinics. The collaboration agreement will deliver online prescribing access and nationwide opportunities to market an erectile dysfunction oral soluble film and a dysmenorrhea gummy through the strategic clinic partnership.

Small Caps reports on EVE Health Group (ASX: EVE) $3 million takeover bid for Australian biotech company Nextract as part of a strategic move to transition from a natural wellness brand into a broader health platform targeting regulated markets. This will allow EVE to tap into the global erectile dysfunction (ED) and dysmenorrhoea (period pain) markets.